StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$172.67+10.49 (+6.47%)

Close on Nov 18, 2026Market cap $11.04BP/E –Yield –

Repligen operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Repligen's operating cash flow for the twelve months ending Sep 30, 2026 was $129.86M, down 0.8% year over year. For fiscal 2025 it was $117.42M, down 33.1% from the year before. Over ten years it grew 22.8% a year on average. The highest annual figure on record is $175.39M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$117.42M-33.1%
FY2024Dec 31, 2024$175.39M+54.0%
FY2023Dec 31, 2023$113.92M-33.8%
FY2022Dec 31, 2022$172.08M+44.6%
FY2021Dec 31, 2021$119.02M+90.0%
FY2020Dec 31, 2020$62.63M-6.8%
FY2019Dec 31, 2019$67.22M+105.1%
FY2018Dec 31, 2018$32.77M+87.8%
FY2017Dec 31, 2017$17.45M+132.0%
FY2016Dec 31, 2016$7.52M-50.0%
FY2015Dec 31, 2015$15.05M-18.2%
FY2014Dec 31, 2014$18.40M-29.0%
FY2013Dec 31, 2013$25.93M+702.3%
FY2011Mar 31, 2011$3.23M–
FY2010Mar 31, 2010-$2.45M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$43.10M-10.4%
Q2 FY2026Jun 30, 2026$32.77M+14.5%
Q1 FY2026Mar 31, 2026$28.30M+88.6%
Q4 FY2025Dec 31, 2025$25.70M-34.4%
Q3 FY2025Sep 30, 2025$48.10M-2.5%
Q2 FY2025Jun 30, 2025$28.61M-32.2%
Q1 FY2025Mar 31, 2025$15.01M-66.4%
Q4 FY2024Dec 31, 2024$39.18M+34.8%
Q3 FY2024Sep 30, 2024$49.32M+25.7%
Q2 FY2024Jun 30, 2024$42.19M+22.4%
Q1 FY2024Mar 31, 2024$44.71M+300.8%
Q4 FY2023Dec 31, 2023$29.07M-53.0%
Q3 FY2023Sep 30, 2023$39.23M-5.2%
Q2 FY2023Jun 30, 2023$34.47M-24.6%
Q1 FY2023Mar 31, 2023$11.15M-51.7%
Q4 FY2022Dec 31, 2022$61.88M+24.7%
Q3 FY2022Sep 30, 2022$41.37M+84.0%
Q2 FY2022Jun 30, 2022$45.72M+21.4%
Q1 FY2022Mar 31, 2022$23.11M+149.5%
Q4 FY2021Dec 31, 2021$49.62M+233.7%
Q3 FY2021Sep 30, 2021$22.48M+4.6%
Q2 FY2021Jun 30, 2021$37.65M+125.0%
Q1 FY2021Mar 31, 2021$9.26M-2.8%
Q4 FY2020Dec 31, 2020$14.87M-15.9%
Q3 FY2020Sep 30, 2020$21.49M-2.2%
Q2 FY2020Jun 30, 2020$16.74M-5.9%
Q1 FY2020Mar 31, 2020$9.53M-2.6%
Q4 FY2019Dec 31, 2019$17.67M+218.2%
Q3 FY2019Sep 30, 2019$21.97M+11.6%
Q2 FY2019Jun 30, 2019$17.79M+198.3%
Q1 FY2019Mar 31, 2019$9.79M+522.6%
Q4 FY2018Dec 31, 2018$5.56M-63.5%
Q3 FY2018Sep 30, 2018$19.68M–
Q2 FY2018Jun 30, 2018$5.96M+111.9%
Q1 FY2018Mar 31, 2018$1.57M+37.1%
Q4 FY2017Dec 31, 2017$15.22M+678.8%
Q3 FY2017Sep 30, 2017-$1.73M–
Q2 FY2017Jun 30, 2017$2.81M–
Q1 FY2017Mar 31, 2017$1.15M–
Q4 FY2016Dec 31, 2016$1.95M–

More Repligen figures

See a number that looks wrong?